Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

K. Edgar · SciRah

Researcher profile · Semantic Scholar

K. Edgar

Share profile

K. Edgar — researcher profile on SciRah

h-index: 19
Works: 51
Citations: 3,316

Most-cited papers

Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome
A. Parks, K. Cook, M. Belvin, Nicholas A Dompe +33 more
2004Nature Genetics840 citations
Semantic Scholar
A hierarchy of self-renewing tumor-initiating cell types in glioblastoma.
Rui-Huan Chen, M. Nishimura, Stephanie M Bumbaca, S. Kharbanda +21 more
2010Cancer Cell577 citations Open access
Semantic Scholar
Oncogenic ERBB3 mutations in human cancers.
B. Jaiswal, Noelyn M. Kljavin, Eric W. Stawiski, Emily Chan +27 more
2013Cancer Cell359 citations Open access
Semantic Scholar
GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
J. Wallin, K. Edgar, Jane Guan, M. Berry +19 more
2011Molecular Cancer Therapeutics227 citations Open access
Semantic Scholar
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.
C. Ndubaku, T. Heffron, S. Staben, M. Baumgardner +25 more
2013Journal of Medicinal Chemistry175 citations Open access
Semantic Scholar
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.
Emily J. Hanan, Marie-Gabrielle Braun, R. Heald, Calum Macleod +31 more
2022Journal of Medicinal Chemistry129 citations Open access
Semantic Scholar
Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
K. Edgar, J. Wallin, M. Berry, L. Lee +4 more
2010Cancer Research128 citations Open access
Semantic Scholar
The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
T. Heffron, R. Heald, C. Ndubaku, Binqing Wei +26 more
2016Journal of Medicinal Chemistry105 citations Open access
Semantic Scholar
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Kyung Song, K. Edgar, Emily J. Hanan, M. Hafner +23 more
2021bioRxiv98 citations Open access
Semantic Scholar
Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
T. Heffron, C. Ndubaku, L. Salphati, B. Alicke +15 more
2016ACS Medicinal Chemistry Letters91 citations Open access
Semantic Scholar
Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941
L. Salphati, H. Wong, M. Belvin, Delia Bradford +4 more
2010Drug Metabolism And Disposition86 citations
Semantic Scholar
Conditional activation of Pik3caH1047R in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations
Wenlin Yuan, Eric W. Stawiski, V. Janakiraman, Emily Chan +17 more
2012Oncogene80 citations Open access
Semantic Scholar
Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier
L. Salphati, T. Heffron, B. Alicke, M. Nishimura +19 more
2012Clinical Cancer Research68 citations Open access
Semantic Scholar
Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer
J. Wallin, Jane Guan, W. Prior, K. Edgar +4 more
2010Science Translational Medicine64 citations
Semantic Scholar
Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes
J. Wallin, Jane Guan, K. Edgar, W. Zhou +13 more
2012PLoS ONE51 citations Open access
Semantic Scholar
The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase α.
T. Heffron, L. Salphati, B. Alicke, J. Cheong +17 more
2012Journal of Medicinal Chemistry50 citations Open access
Semantic Scholar
Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform.
S. Staben, C. Ndubaku, N. Blaquiere, M. Belvin +28 more
2013Bioorganic & Medicinal Chemistry Letters23 citations Open access
Semantic Scholar
Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies
Rebecca Hong, K. Edgar, Kyung Song, S. Steven +12 more
201821 citations Open access
Semantic Scholar
The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase
K. Hoeflich, Jane Guan, K. Edgar, C. O'Brien +5 more
2016Genes & cancer20 citations Open access
Semantic Scholar
Abstract DDT02-01: Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors.
A. Olivero, T. Heffron, M. Baumgardner, M. Belvin +46 more
201319 citations
Semantic Scholar
Synthetic Lethality of Retinoblastoma Mutant Cells in the Drosophila Eye by Mutation of a Novel Peptidyl Prolyl Isomerase Gene
K. Edgar, M. Belvin, A. Parks, Kellie Whittaker +19 more
2005Genetics16 citations
Semantic Scholar
Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition
K. Edgar, Lisa M. Crocker, Eric Cheng, Marie-Claire Wagle +9 more
2014Genes & cancer15 citations Open access
Semantic Scholar
Recombinant juvenile hormone esterase, an effective tool for modifying juvenile hormone‐dependent expression of the early trypsin gene in mosquitoes
K. Edgar, F. G. Noriega, B. Bonning, Michael A. Wells
2000Insect molecular biology (Print)15 citations
Semantic Scholar
Neuroendocrine factors affecting the steady-state levels of early trypsin mRNA in Aedes aegypti.
F. G. Noriega, K. Edgar, W. Goodman, Deepa K. Shah +1 more
2001Journal of insect physiology12 citations
Semantic Scholar
Abstract 156: Preclinical characterization of GDC-0077, a specific PI3K alpha inhibitor in early clinical development
K. Edgar, Emily J. Hanan, S. Staben, S. Schmidt +10 more
20179 citations
Semantic Scholar
Abstract P2-17-01: The PI3K inhibitor GDC-0032 is selectively potent against PIK3CA mutant breast cancer cell lines and tumors
J. Wallin, K. Edgar, Jane Guan, D. Sampath +3 more
20138 citations
Semantic Scholar
Abstract S6-04: The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action
L. Friedman, K. Edgar, Kyung Song, S. Schmidt +8 more
20167 citations
Semantic Scholar
Quantitative phosphoproteomic analysis of the PI3K‐regulated signaling network
Florian Gnad, J. Wallin, K. Edgar, Sophia Doll +8 more
2016Proteomics5 citations
Semantic Scholar
Abstract 146: The PI3K inhibitor, taselisib, has a unique mechanism of action that leads to enhanced potency in PIK3CA mutant models
Kyung Song, K. Edgar, D. Kirkpatrick, L. Phu +8 more
20174 citations
Semantic Scholar
Abstract P3-11-23: GDC-0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone-positive breast cancer models
K. Edgar, Rebecca Hong, Kyung Song, S. Schmidt +8 more
2020Poster Session Abstracts3 citations
Semantic Scholar
Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel PI3K Inhibitor 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4- morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941)
L. Salphati, H. Wong, M. Belvin, Delia Bradford +4 more
20103 citations
Semantic Scholar
Effects of PI3K Inhibition on Afucosylated Antibody–Driven FcγRIIIa Events and Phospho-S6 Activity in NK Cells
V. Romeo, S. Gierke, K. Edgar, S. Liu
2019Journal of Immunology2 citations Open access
Semantic Scholar
220 POSTER Combination of class I PI3K inhibitor, GDC-0941, with standard of care therapeutics results in enhanced anti-tumor responses in human cancer models in vitro and in vivo
D. Sampath, M. Belvin, Jane Guan, K. Edgar +6 more
20082 citations
Semantic Scholar
217 POSTER Pre-clinical evaluation of efficacy and PK/PD biomarkers of GDC-0941, a potent class 1 PI3K inhibitor
Sonal Patel, D. Sampath, M. Belvin, Anthony E. Brown +6 more
20082 citations
Semantic Scholar
Abstract 2672: Characterization of the enhanced potency of PI3K inhibitor taselisib (GDC-0032) in PI3K mutant cell lines and models
K. Edgar, M. Nannini, Rebecca Hong, C. Eigenbrot +5 more
20151 citations
Semantic Scholar
Abstract #3392: Transient pAkt increase after chemo exposure predicts strength of synergy for combinations of the PI3K inhibitor GDC-0941 and chemotherapeutics
J. Wallin, K. Edgar, Jane Guan, L. Friedman +1 more
20091 citations
Semantic Scholar
Abstract C201: A novel potent and selective inhibitor of PI3K/mTOR, GDC‐0980, currently in phase I clinical trials
L. Friedman, M. Belvin, L. Berry, M. Berry +17 more
20091 citations
Semantic Scholar
Abstract 7120: Rinzimetostat, an allosteric EED inhibitor with best-in-class properties for the treatment of prostate cancer, is effective in PRC2 methyltransferase-resistant settings in preclinical studies
Xi Chen, Livia Ulicna, E. López-Fuentes, Anjana Ramnath +10 more
2026Cancer Research0 citations
Semantic Scholar
Abstract 594: ORIC-613, a potential first- and best-in-class, orally bioavailable, potent and selective PLK4 inhibitor with synthetic lethality in TRIM37 high cancer models
K. Edgar, S. McRee, Gina Andretta, Chelsea Chen +16 more
2024Cancer Research0 citations
Semantic Scholar
Abstract 4998: Selective PLK4 inhibition demonstrates synthetic lethality in TRIM37 amplified neuroblastoma and breast cancer models while less selective inhibitors do not
S. McRee, Chelsea Chen, C. Colas, Wie Fang +15 more
2023Cancer Research0 citations
Semantic Scholar
Abstract 2633: Discovery of novel, highly selective inhibitors of PLK4 that demonstrate in vivo regressions in TRIM37 high xenografts
K. Edgar, Amy Young, Jared Moore, Xi Chen +12 more
2022Cancer Research0 citations
Semantic Scholar
Abstract PR03: Selective degradation of mutant PIK3CA promotes increased mutant specificity in a subset of PI3K ATP-competitive inhibitors
Lanh Nguyen, K. Edgar, Kyung Song, S. Schmidt +15 more
2020Oral Presentations - Proffered Abstracts0 citations
Semantic Scholar
Preclinical development of the PI3K Alpha selective and PIK3CA Mutant selective inhibitor GDC-0077 and prediction of its human pharmacokinetics
Jodie Pang, M. Baumgardner, Marie-Gabrielle Braun, J. Cheong +11 more
2019Drug Metabolism and Pharmacokinetics0 citations
Semantic Scholar
p110delta/p85alpha with GDC-0326
T. Heffron, R. Heald, C. Ndubaku, B.-Q. Wei +26 more
20160 citations
Semantic Scholar
p110alpha/p85alpha with compound 5
T. Heffron, R. Heald, C. Ndubaku, Binqing Wei +26 more
20160 citations
Semantic Scholar
p110alpha with GDC-0326
T. Heffron, R. Heald, C. Ndubaku, Binqing Wei +26 more
20160 citations
Semantic Scholar
Abstract B37: Mechanisms of acquired resistance to the PI3K inhibitor GDC-0941 in breast cancer cell lines
K. Edgar, Ling Hwu, K. Walter, M. Lackner +2 more
20150 citations
Semantic Scholar
Abstract 4470: Mechanisms of acquired resistance to the PI3K inhibitors in colorectal cancer cell lines.
K. Edgar, Marie-Claire Wagle, Yi-Bing Yan, M. Belvin +2 more
20130 citations
Semantic Scholar
GDC-0980IsaNovelClassIPI3K/mTORKinaseInhibitorwith RobustActivityinCancerModelsDrivenbythePI3KPathway
J. Wallin, K. Edgar, Jane Guan, M. Berry +19 more
20110 citations
Semantic Scholar
Abstract 2787: Discovery of GDC-0980, a selective PI3K/mTOR inhibitor in clinical trials
D. Sutherlin, M. Belvin, Linda Bao, L. Berry +21 more
20110 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Friedman×36
Invite
L. Friedman — researcher profile on SciRah
J. Wallin×28
Invite
J. Wallin — researcher profile on SciRah
D. Sampath×25
Invite
D. Sampath — researcher profile on SciRah
M. Belvin×22
Invite
M. Belvin — researcher profile on SciRah

×21

Invite

L. Salphati — researcher profile on SciRah

Invite

Jodie Pang — researcher profile on SciRah

Invite

W. Prior — researcher profile on SciRah

Invite

A. Olivero — researcher profile on SciRah

Invite

S. Staben — researcher profile on SciRah

Invite

L. Lee — researcher profile on SciRah

Invite

C. Lewis — researcher profile on SciRah

J. Nonomiya×12

Invite

J. Nonomiya — researcher profile on SciRah